By IDSE News Staff
The FDA approved raltegravir (Isentress HD, Merck), a new 1,200-mg once-daily version of the company’s integrase inhibitor, Isentress, for the treatment of adults and pediatric patients with HIV.
Isentress HD should be administered orally as two 600-mg film-coated tablets with or without food, with other antiretroviral agents, for the treatment of HIV-1 infection in adults and children weighing at least 40 kg who are treatment-naive or whose virus has been suppressed on